Lynozyfic

Product Overview

About Lynozyfic

Lynozyfic can only be obtained with a prescription, and treatment should be started and supervised by a doctor experienced in the treatment of multiple myeloma.

What it is used for

Not specified in the provided information.

How it is used

Lynozyfic should be given in a facility with immediate access to emergency equipment and appropriate medical support to manage side effects such as cytokine release syndrome (CRS), infusion-related reactions (IRR), and immune effector cell-associated neurotoxicity syndrome (ICANS). It is given as an infusion (drip) into a vein. Treatment is given once a week for the first 13 weeks, with the dose being progressively increased for the first 3 weeks. It is then given every other week. Starting from week 24, Lynozyfic may be given every four weeks, depending on the response to treatment. Treatment can continue as long as the patient benefits from it and the side effects are not too severe.

How it works

The active substance in Lynozyfic, linvoseltamab, is a monoclonal antibody (a type of protein) which is described as ‘bispecific’ because it recognises and attaches to two targets simultaneously: the B cell maturation antigen (BCMA) which is present on the surface of multiple myeloma cancer cells, and CD3, a protein present on the surface of T cells (cells in the immune system). By attaching to these targets, linvoseltamab brings the cancer cells and T cells together. This activates the T cells, which then kill the multiple myeloma cancer cells.

Active substance: linvoseltamab

Source: EMA EPAR